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Bodansky (1954a) recently described a method for the determination of serum
isomnerase and examined the extent to which the serum enzyme activity can be
correlated with clinical and biochemical evidence of tumour growth. He found
good correlation in breast and prostatic cancer (Bodansky, 1954b, 1955).
In view of the considerable isomerase activity shown by erythrocytes and
leukocytes, we have determined the serum isomerase concentrationi in diseases
involving the cellular elements of the blood.
MIIATERIALS AND METHODS
The serum phosphohexose isomerase activity was determined according to the
mnethod of Bodansky (1954a). This determination was carried out on fresh serum
obtained from normal controls, patients with variousnon-malignantdiseaseswith
normal leukocyte counts, patients with chronic myelocytic and chronic lympho-
cytic leukaemia, and patients with leukocytosis due to infection. Many of the
leukemia group were under treatment at the time of isomerase estimation. Those
patients with chronic myelocytic leukemia were receiving radiation or dimethyl-
sulphonoxylbutane (Myleran®), and those with chronic lymphocytic leukemia,
radiation or p-(Di-2-chloroethylamino)-phenylbutyric acid (CB1348).
RESULTS
Fig. 1 shows graphically the values obtained. The results shown in the myelo-
cytic and lymphocytic groups represent the initial value obtained in the particular
patient, as in the chronic myelocytic leukemia group subsequent values fell as
therapy was instituted or continued.
The values obtained by us in the normal and non-malignant disease groups are
in reasonably good agreement with those of Bodansky who found a mean of 20
and a standard deviation of 8 in the former and a mean of 18 and a standard
deviation of 5-5 in the latter. Our results, however, show a greater spread down-
wards towards lower values.
Fig. 1 also demonstrates the high values in chronic myelocytic leukemia as
compared with the other groups. The lowest values in this group were obtained
from patients who had been on Myleran therapy for many months prior to the
isomerase estimation.
Fig. 2 shows the relationship between the serum isomerase and the number of
cells of the myelocytic series in chronic myelocytic leukemia before and after
treatment, chronic lymphocytic leukemia and infection. In the chronic myelocyticSERUM ISOMERASE IN LEUKEMIA
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leukemia group there would seem to be parallel increases in the serum isomerase
and the absolute granulocyte count of the peripheral blood. Fig. 2 also shows the
decrease in serum isomerase in chronic myelocytic leukemia treated with Myleran.
This decrease in activity did not always parallel the total leukocyte or granulocyte
count. In some patients it occurred within a few weeks; in others many months
elapsed before a change in serum isomerase could be detected.
DISCUSSION
Many cells and tissues, including the leukocytes and erythrocytes, have a
high isomerase activity. Bodansky (1954b, 1955) has suggested that the rise in
serum isomerase in metastatic malignancy may be due to either an excessive
production ofthe enzyme in the new growth or to the easier access into the blood
stream of the enzyme from the normal tissues in juxtaposition to the invading
tumour. The high levels in chronic myelocytic leukemia may be due to increased
production ofthe enzyme by the leukemic cells or more rapid loss ofenzyme from
the cells into the serum. The association ofhigh serum isomerase values with the
very high granulocyte counts may indicate formation by,orreleaseof, the enzyme
from this cell series. The normal values in chronic lymphocytic leukemia suggest
that thelymphocytes do not possess or release isomerase to the same degree as do
the granulocytes. The serum isomerase does not reflect the total white blood
cell count as those cases ofchronic lymphocytic leukemia with a high total leuk-
ocyte count (up to 295,000/c.mm.) had normal serum isomerase levels. We are
now estimating the enzyme in separated leukocytes in an attempt to demonstrate
differences in the two series of cells.
Although the total leukocyte count and the granulocyte count were found to
be elevated in the infection group, the isomerase was for the most part within
normal limits. However, the total granulocyte counts in this group still fell far
below those obtained in chronic myelocytic leukemia.
Another possible explanation of the high levels found in chronic myelocytic
leukemia might be that bone erosion from the rapidly proliferating myeloid series
expanding the medullary cavity facilitates the liberation of isomerase from
adjacent tissue. However, the bone marrow invasion and replacement in chronic
lymphocytic leukemia is without such an effect on the serum isomerase.
SUMMARY
The serum phosphohexose isomerase acivity was estimated in a normal group
and in patients with non-malignant disease, chronic myelocytic and chronic
lymphocytic leukemia and leukocytosis due to acute infectious processes. It was
found to be elevated in chronic myelocytic leukemia but not inthe othergroups.
In the chronic myelocytic group the isomerase levels fell following treatment.
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